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Summary Endoglin, or CD105, is a cell membrane glyco-
protein that is overexpressed on proliferating endothelial cells
(EC), including those found in malignancies and choroidal
neovascularization. Endoglin mediates the transition from
quiescent endothelium, characterized by the relatively domi-
nant state of Smad 2/3 phosphorylation, to active angiogenesis
by preferentially phosphorylating Smad 1/5/8. The monoclo-
nal antibody TRC105 binds endoglin with high avidity and is
currently being tested in phase 1b and phase 2 clinical trials. In
this report, we evaluated the effects of TRC105 on primary
human umbilical vascular endothelial cells (HUVEC) as a
single agent and in combination with bevacizumab. As single
agents, both TRC105 and bevacizumab efficiently blocked
HUVEC tube formation, and the combination of both agents
achieved even greater levels of inhibition. We further assessed
the effects of each drug on various aspects of HUVEC func-
tion. While bevacizumab was observed to inhibit HUVEC
viability in nutrient-limited medium, TRC105 had little effect
on HUVEC viability, either alone or in combination with
bevacizumab. Additionally, both drugs inhibited HUVEC
migration and induced apoptosis. At the molecular level,
TRC105 treatment of HUVEC lead to decreased Smad 1/5/8
phosphorylation in response to BMP-9, a primary ligand for
endoglin. Together, these results indicate that TRC105 acts as
an effective anti-angiogenic agent alone and in combination
with bevacizumab.
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Introduction
Anti-angiogenic therapies have emerged as prominent ap-
proaches for cancer treatment over the past decade [1, 2].
Tumor progression is heavily dependent on angiogenesis for
primary tumor growth and metastasis. Anti-angiogenic agents
inhibit an organism’s potential to develop new blood vessels
and prevent tumor growth by blocking access to oxygen and
nutrients. Bevacizumab (Avastin™), the first approved anti-
angiogenic drug, binds vascular endothelial growth factor
(VEGF) and was approved by Food and Drug
Administration for the treatment of metastatic colorectal can-
cer in 2004 [3]. Bevacizumab is currently approved for mul-
tiple cancer indications, based on the prolongation of patient
survival, clinically confirming the value of anti-angiogenic
therapeutics which target the VEGF pathway [4].
Despite the widespread use of anti-angiogenic agents, the
clinical benefit is limited and transient [5]. Such therapies
appear to benefit a subset of cancer patients; and those who
respond ultimately progress. This phenomenon is not surpris-
ing given that angiogenesis is regulated through a complex
interplay of multiple pathways. When VEGF-mediated sig-
naling is blocked by bevacizumab, other angiogenic pathways
are activated, resulting in drug resistance. Therefore, combin-
ing drugs that target different angiogenic pathways may be a
more effective strategy. Currently, more than forty anti-
angiogenic drugs are being tested in clinical trials [6].
Endoglin is a homodimeric transmembrane glycoprotein
highly expressed on proliferating endothelial cells [7, 8]. As a
co-receptor for TGF-β and for bone morphogenic protein
(BMP), endoglin associates with ALK1, an endothelial cell-
specific type-I receptor, to promote downstream Smad 1/5/8
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phosphorylation and endothelial cell proliferation, primarily
in response to BMP [9]. Recent data by Nolan-Stevaux et al.
strongly supports that endoglin-dependent BMP signaling is
the critical pathway for Smad 1/5/8 activation in primary
HUVEC cells [10]. In contrast, in the absence of endoglin,
another type-I receptor, ALK5, promotes downstream Smad
2/3 phosphorylation that maintains a state of EC quiescence.
This balance between Smad 1/5/8 and Smad 2/3 phosphory-
lation regulates EC homeostasis [11]. When Smad 1/5/8 sig-
naling predominates, EC undergo proliferation, migration,
and promote angiogenesis; when Smad 2/3 signaling predom-
inates, EC remain quiescent. Consistent with its angiogenic
role, endoglin is markedly upregulated on the endothelium of
malignancies [8]. Dense staining of endoglin has been ob-
served in the angiogenic blood vessels of more than 10 types
of tumor tissues and correlated with poor prognosis [12, 13],
suggesting its potential as a target for clinical intervention
[14].
TRC105 is a monoclonal antibody that binds endoglin with
high avidity and is currently being evaluated in phase 1b and
phase 2 clinical trials [15]. TRC105 exhibited promising
safety and activity in the first-in-human, phase 1 trial [16].
The phase 1, dose escalation study determined the recom-
mended dose for phase 2 to be 10 mg/kg weekly, or
15 mg/kg every two weeks. Both doses resulted in high
circulating TRC105 levels in patients plasma, with peak con-
centrations ranging from 200 to 600 μg/ml [16].
Due to the fact that TRC105 targets an essential angiogenic
pathway distinct from the VEGF pathway targeted by
bevacizumab, the combination of both drugs may provide
greater activity. In this study, we tested the effects of
TRC105 and bevacizumab as single agents, as well as in
combination, on EC tube formation, viability, migration, and
apoptosis. Further, we assessed the effects of TRC105 on
patterns of Smad phosphorylation in HUVEC cells.
Materials and methods
Cell culture
Low passage HUVEC cells were purchased from Clonetics/
Lonza (Walkersville, MD). HUVEC were cultured in either
regular medium containing EBM-2 basic medium supple-
mented with EGM-2 MV single aliquots; or nutrient-
limited medium containing EBM-2 basic medium sup-
plemented with 0.5 % FBS and 30 ng/ml VEGF (Lonza,
Walkersville, MD). All cells were maintained in a
37 °C, 5 % CO2 incubator. TRC105 (5 mg/ml) was
provided by Tracon Pharmaceuticals, Inc. (San Diego,
CA). Bevacizumab (25 mg/ml) was from Genentech Inc.
(San Francisco, CA).
HUVEC tube formation
HUVECwere pre-treated with 100μg/ml TRC105, 100 ng/ml
bevacizumab, or both drugs for 8 h in regular medium. Human
IgG (Jackson Immuno Research, West Grove, PA) was used
as an isotype control. The cells were harvested and maintained
in drug containing medium, and 1.5×104 HUVEC were inoc-
ulated onto pre-polymerized ECMatrix gel (In vitro angiogen-
esis assay kit, Chemicon, Temecula, CA). After 16 h incuba-
tion, cells were visualized using the Axiobserver in the Duke
Light Microscopy Core facility (LMCF). Closed polygons
were counted, and total tube length measured with the
MetaMorph software (MDS Analytical Technologies,
Sunnyvale, CA).
HUVEC viability (MTS assay)
HUVEC were inoculated at 5,000 cell/well onto a 96-well
plate. After overnight incubation, cells were treated with either
regular or limited medium containing either TRC105,
bevacizumab, the combination of both drugs, or IgG control
for 72 h with daily medium change. At the termination of the
assay, 20 μl MTS tetrazolium compound (CellTiter 96
Aqueous One Solution Cell Proliferation Assay, Promega,
Madison, WI) was added to each well, absorbance at
490 nm was recorded 4 h later following the manufacturer’s
protocol.
HUVEC migration
HUVEC (8×105/well) were inoculated onto a 6-well plate.
After a confluent monolayer had formed overnight, a scratch
was introduced with a sterile 200 μl tip. Cell debris was
removed by washing with PBS, fresh regular medium con-
taining either IgG isotype control (100 μg/ml), TRC105
(100 μg/ml), bevacizumab (100 ng/ml), or the combination
of TRC105 (100 μg/ml) and bevacizumab (100 ng/ml) was
supplied. Scratch filling was monitored using a live cell sta-
tion in Duke LMCF over a period of 16 h. Percentage of
scratch filling was calculated as (Distance between gap edges
at time point 0 - distance at time point X)/distance at time
point 0 *100 %, using MetaMorph software.
HUVEC apoptosis
HUVEC (1×105/well) were inoculated onto a 6-well plate in
which a gelatin-coated glass slide had been placed at the
bottom. HUVEC were maintained in regular or limited medi-
um with TRC105, bevacizumab, or the combination of both
for 72 h. Fresh medium with drugs were applied daily. Cells
were then fixed in methanol: acetic acid (3:1) for 5 min at
4 °C, washed three times with PBS, and stained with Hoechst
33,342 (5 μg/ml, Calbiochem, La Jolla, CA) for 10 min at
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room temperature. Then cells were washed three more times,
the slides removed from plate wells, and mounted onto a glass
carrier with Vectashield mounting medium for fluorescence
(Vector Laboratories, Inc., Burlingame, CA). Apoptotic nuclei
were visualized under a fluorescence microscope in Duke
LMCF. Ten representative fields were imaged, cells counted,
and the ratio of apoptotic nuclei vs. total nuclei was calculated
with MetaMorph software.
Smad signaling in HUVEC
HUVEC (5×105/well) were inoculated onto a 6-well plate and
incubated overnight. Cells were serum starved in EBM-2,
0.1 % BSA, and 10 mM Hepes for 4 h. Cells were pretreated
with TRC105 or isotype control for 1 h, and stimulated with
0.2 ng/ml BMP-9, or 0.25 ng/ml TGF-β1 (R&D systems,
Minneapolis, MN) for 1 h. Then cells were put on ice imme-
diately, cell lysate harvested in lysis buffer: 20 mM Hepes,
2 mM MgCl2, 1 mM EDTA and EGTA, 150 mM NaCl, 1 %
Triton X-100, 0.1 % SDS, and protease inhibitors. After
centrifugation at 16,000×g for 10 min, cell debris and nuclei
were removed, and cell lysates were snap frozen before stored
at −80 °C freezer.
Western immunoblots
Cell lysates (10 μg) were separated on a 4–20 % SDS-PAGE
gel. Blots were incubated with rabbit-anti-phos-Smad1/5/8,
anti-Smad 1, anti-Phos-Smad2, or anti-Smad 2/3 (Cell
Signaling, Danvers, MA), as well as mouse anti-β-actin for
loading control, overnight at 4 °C. LI-COR specific goat anti-
rabbit, or goat anti-mouse IgG secondary antibody (1:5,000)
was added and incubated for 1 h at room temperature.
Immunoblots were analyzed using the Odyssey imaging sys-
tem (LI-COR Biotechnology, Lincoln, NE).
Results
TRC105 and bevacizumab inhibit HUVEC tube formation
To evaluate the anti-angiogenic function of TRC105, HUVEC
tube formation was first tested. Since TRC105 is a chimeric
antibody cloned into an IgG1 backbone, human IgG molecule
was used as an isotype control. As shown in Fig. 1a, over-
night incubation of HUVEC with IgG control (100 μg/ml) on
a matrigel leads to the development of extensive tubular
networks, which can be quantified by counting the number
of closed polygons and total length of capillary tubes.
TRC105 (100 μg/ml) and bevacizumab (100 ng/ml) treated
cells showed impaired tube formation, exhibited by less dense
tube network and some disrupted regions. Strikingly, when
cells were treated with both agents, only partially formed
tubes and fewer closed polygons could be detected. After data
normalization, polygon formation was inhibited by 40–50 %
using either drug alone and by more than 80 % using the
combination of both drugs. The combination of drugs is
significantly more effective in inhibiting polygon formation
than either drug used alone (p≤0.05; Fig. 1b). The total length
of tubes, an earlier biologic step reflecting mainly cell migra-
tion and alignment, was less affected, exhibiting 5–10 %
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Fig. 1 TRC105 and bevacizumab inhibit HUVEC tubular network for-
mation in in vitro angiogenesis assays. a. HUVEC cells growing on
matrigel overnight in the presence of IgG control (100 μg/ml) formed
extensive tube networks. TRC105 (100 μg/ml), bevacizumab
(100 ng/ml), or the combination of both drugs was added and the effects
on polygon formation and tube length were visualized. b. Normalized bar
graph showing the fold inhibition on polygon formation and tube length.
Each column represents the mean±SD of three independent experiments.
*p<0.05 compared to IgG control
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inhibition from each drug alone, and more than 30 % inhibi-
tion using the combination of drugs. Overall, these results
indicate that both TRC105 and bevacizumab inhibit EC tube
formation, and that the combination of drugs achieved more
robust inhibition than either drug alone.
Effect of TRC105 and bevacizumab on HUVEC viability
Since EC tube formation is a comprehensive assay reflecting
multiple cellular processes such as proliferation, migration/
alignment, and apoptosis, we further examined each function-
al aspect individually. To evaluate cell viability, HUVECwere
treated with increasing concentrations of drug or isotype con-
trol for 72 h, followed by the addition of the MTS tetrazolium
compound, which undergoes a color change when bioreduced
by metabolically active cells. While little to no effect of IgG
was observed at the ng/ml range (data not shown), IgG at the
μg/ml range inhibited HUVEC viability. At this dose range,
TRC105 (μg/ml) elicited comparable inhibition to IgG (μg/
ml) alone, suggesting the inhibition observed in response to
TRC105 was an IgG non-specific effect. In regular medium,
bevacizumab showed no appreciable inhibition on HUVEC
viability when tested at concentrations of 100 ng/ml to
1 μg/ml (Fig. 2a). Higher concentrations of bevacizumab
(100 μg/ml to 1 mg/ml) were also tested, but again, the effects
were negligible (data not shown). When both drugs were
combined, the inhibitory effect on HUVEC viability was
essentially the same as IgG alone.
The lack of a bevacizumab effect on HUVEC viability in
serum-containing medium was not surprising. The high abun-
dance of growth factors present in the serum-containing me-
dium, including FGF, EGF, VEGF, and IGF, all can serve as
potential compensatory factors upon VEGF blockage. To
isolate the effect of TRC105 and bevacizumab on VEGF-
specific cell viability, we optimized a nutrient-limited medium
that excluded all other growth factors (i.e., FGF, EGF, and
IGF) except VEGF. Limited medium was formulated contain-
ing 0.5 % FBS and 30 ng/ml VEGF. In this setting,
bevacizumab produced a significant drug-specific dose-
dependent inhibition on HUVEC viability (p<0.01 vs. IgG
control, Fig. 2b), while TRC105-mediated inhibition at μg/ml
concentrations was less robust and non-specific. A closer
comparison among bevacizumab alone, bevacizumab+IgG,
bevacizumab+TRC105 treated cells revealed little enhance-
ment when TRC105 was added to bevacizumab. Therefore,
the combination of both drugs did not lead to greater inhibi-
tion of HUVEC viability as compared to bevacizumab alone.
TRC105 and bevacizumab inhibit HUVEC migration
The in vitro scratch assay was used to measure cell motility
[17]. HUVEC cells were allowed to grow to confluence, then
a gap was introduced into the cell monolayer and the process
of cell migration was monitored over a period of 16 h. In
regular medium, untreated cells refilled the gap within 10–
11 h. As shown in Fig. 3, incubation of HUVEC in the
presence of 100 μg/ml TRC105 significantly delayed endo-
thelial cell migration (p<0.05). Treatment with 100 ng/ml
bevacizumab achieved similar effects (p<0.01). Treatment
with both drugs inhibited migration more than observed with
either TRC105 or bevacizumab alone (p≤0.01) (Fig. 3). IgG
isotype control at 100μg/ml showed no inhibition onHUVEC
migration (data not shown). When scratch filling was assessed
in limited medium, HUVEC cells did not migrate well and
never reached confluence in the absence of drugs, even after
24 h post scratch.











































Fig. 2 Effect of TRC105 and
bevacizumab on HUVEC
viability. Subconfluent HUVEC
were subjected to TRC105 (100–
1,000 μg/ml), bevacizumab
(100–1,000 ng/ml), both drugs, or
IgG (100–1,000 μg/ml) treatment
for 3 days in regular medium (a)
and limited medium (b). Cell
viability was measured by MTS
tetrazolium assay, and absorbance
at 490 nm was reported. Data
represent the mean±SD of three
independent experiments. **
p<0.01 compared to IgG control
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TRC105 and bevacizumab induce HUVEC apoptosis
To test the apoptotic effects of TRC105 and bevacizumab,
HUVEC were first treated with each drug individually in
regular or limited medium for 72 h, and then subjected to
Hoechst staining (Fig. 4). Condensed, fragmented nuclei
representing apoptotic features were counted, and the ratio
of apoptotic nuclei vs. total nuclei was plotted. Camptothecin
(4 μg/ml) was used as a positive control and induced more
than a 30-fold increase in the apoptotic cell ratio after over-
night incubation (data not shown). IgG isotype control was
indistinguishable from the no drug control (data not shown)
[18]. In regular medium, TRC105 exhibited a small, yet
significant, dose-dependent induction of apoptosis, with
a 3-fold increase at 100 μg/ml, and a 6-fold increase at
1,000 μg/ml, versus no-drug control (Fig. 4a).
Bevacizumab induced apoptosis to similar levels as seen
with TRC105 (p<0.01 vs. control). Additive effects
were not observed when the drugs were combined, as
the induction of apoptosis was similar compared to
either single agent.
In limited medium, the basal apoptosis rate was higher than
that in regular medium (5 % vs. 1.2 %). TRC105 elicited a 2-
fold induction of apoptosis at 1,000 μg/ml. Bevacizumab was
a more potent inducer of apoptosis under these conditions,
achieving a 3.8 fold increase at 1,000 ng/ml (p<0.001 vs.
control). As was seen with regular medium, the combination
of drugs in limited medium did not further increase apoptosis
(Fig. 4b).
TRC105 differentially modulates Smad 1/5/8 and Smad 2/3
signaling pathways in response to BMP-9 and TGF-β1
Multiple factors have been identified as endoglin ligands,
including TGF-β1 and TGF-β3 [7], as well as BMP-9 and
BMP-10 [19]. To investigate these signaling modalities,
serum-starved HUVEC cells were exposed to either BMP-9
or TGF-β1. As shown in Fig. 5, BMP-9 strongly acti-
vated Smad 1/5/8 phosphorylation (~30 fold), but had
little effect on Smad 2. In contrast, TGF-β1 exposure
mainly activated Smad 2 phosphorylation (~5 fold), but
not Smad 1/5/8 signaling.
To explore the underlying molecular mechanisms contrib-
uting to the effects of TRC105 on HUVEC function, the
phosphorylation status of Smad 1/5/8 and Smad 2 was inves-
tigated. When HUVEC were pre-incubated with increasing
amounts of TRC105, BMP-9-induced Smad 1/5/8 phosphor-
ylation was inhibited across all doses of TRC105 tested
(Fig. 5, panel b), including a dose of 0.2 μg/mL, which is
the TRC105 concentration expected, based on binding avidity
studies, to saturate endoglin binding sites on HUVECs. In
contrast, TRC105 treatment only marginally modulated
TGF-β1 induced Smad 2 phosphorylation (panel C). Both





















Fig. 3 TRC105 and bevacizumab inhibit HUVEC migration. HUVEC
confluent monolayers were scratched to create a gap, exposed to TRC105
(100 μg/ml), bevacizumab (100 ng/ml), or the combination of TRC105
(100 μg/ml) and bevacizumab (100 ng/ml), and monitored for cell mi-
gration for 16 h. Percentage of scratch filling at 10 h post scratch was
shown. Each column represents the mean±SD of three independent





























































































Fig. 4 TRC105 and bevacizumab induce HUVEC apoptosis. Apoptosis
was evaluated by Hoechst staining after HUVEC were treated with
TRC105 (100 or 1,000 μg/ml), bevacizumab (100 or 1,000 ng/ml), or
the combination of drugs at the lower doses (100 μg/ml TRC105 and
100 ng/ml bevacizumab) for 3 days. a. Regular medium. b. Limited
medium. Each column represents the mean±SD of three independent
experiments. ** p<0.01, *** p<0.001 compared to no drug control
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inhibition of either Smad 1/5/8 or Smad 2 phosphorylation
(data not shown).
Discussion
In this study, we evaluated the anti-angiogenic drug TRC105,
and its combination with bevacizumab, in a series of HUVEC
functional assays. Initially, individual drugs were tested over a
broad range of dosing levels under each assay condition. In
every assay system, doses that induced moderate effects (typ-
ically around 25–30 % inhibition) were chosen for these
analyses in order to detect potential additive or synergistic
effects with both drugs. For most assays, the dose of TRC105
was empirically determined to be 100 μg/ml, as lower doses
exhibited little effect on HUVEC function. This dose is clin-
ically relevant as pharmacokinetic analyses revealed that the
serum concentration of TRC105 following dosing in ad-
vanced cancer patients at the recommended phase 2 dose
ranged from 200 to 600 μg/ml [16]. For bevacizumab, the
dose tested in most assays was empirically determined to be
100 ng/ml.
Despite the fact that TRC105 and bevacizumab are both
monoclonal antibodies that block angiogenesis, the targets of
each drug are different and utilize distinct mechanisms.
Endoglin is an integral cell membrane receptor located on
proliferating endothelial cells [20], whereas VEGF is a soluble
angiogenic factor that is primarily released by tumor cells and
tumor-associated stromal cells [21, 22]. Therefore, combining
TRC105 and bevacizumab has the potential to block comple-
mentary pathways leading to improved efficacy.
We observed that individually, both TRC105 and
bevacizumab blocked HUVEC tube formation, and the most
robust inhibition was achieved when both drugs were com-
bined (Fig. 1). The tube formation assay is a powerful tool to
monitor ECs during vascular network formation, representing
an end-point evaluation of the complicated interplay among
many processes, including proliferation, differentiation, mi-
gration, apoptosis, etc. To further interrogate these processes,
we next investigated specific EC functional biology in more
defined assay systems.
When given at 100–1,000 μg/ml levels, TRC105 and its
isotype control (IgG) similarly inhibited HUVEC viability, in
both regular and nutrient-limited medium (Fig. 2). In contrast,
although bevacizumab elicited little effect on HUVEC viabil-
ity in regular medium, it showed dose-dependent, drug-
specific inhibition in limited medium (Fig. 2b). While
TRC105 had little effect on HUVEC viability, several obser-
vations are noteworthy. First, contrary to bevacizumab,
TRC105 elicited no inhibitory effect on HUVEC growth in
nutrient-limited medium. Second, given that the steady state
plasma concentration of TRC105 in patients is inμg/ml range,
the potential non-specific effect of IgG on EC growth should
be considered. Third, Anderberg et al., reported that genetic
knockdown of endoglin sensitizes tumors to VEGF inhibition
[23], advocating for the potential benefit of co-administration
of these drugs. The underlying mechanism is unlikely to be an
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Fig. 5 TRC105 diminished BMP-9 induced Smad 1/5/8 signaling in
HUVEC cells. a. Western blotting showing the levels of phosphorylated
Smad 1/5/8, total Smad 1, phos-Smad 2, total Smad 2/3 in response to the
stimulation of BMP-9 or TGF-β1. Cells were pre-incubated with various
doses of TRC105 for 1 h prior to stimulation. b. Effect on Smad 1/5/8
signaling as revealed by the ratio of phos-Smad 1/5/8 vs. total Smad 1. c.
Effect on Smad 2 signaling as revealed by the ratio of phos-Smad 2 vs.
total Smad 2/3. 0.2, 100, 1,000 depict TRC105 doses of 0.2, 100, and
1,000 μg/ml, respectively
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effect on EC growth/viability, as suggested by our MTS data
and suggests that the inhibition of HUVEC tube formation is
not due to the impact of these agents on cell viability.
The effect of endoglin on cell motility is controversial.
While endoglin is considered to be an inhibitor of cell migra-
tion through its extracellular RGD domain that binds to inter-
cellular matrix proteins [24], evidence exists that endoglin
promotes ALK1 signaling, leading to increased cell mobility
[25]. Additionally, endoglin has been shown to antagonize the
inhibitory effect of TGF-β1 on HUVEC migration, suggest-
ing a positive role of endoglin in HUVEC motility [26]. Our
scratch assay data support the latter hypothesis (Fig. 3).
TRC105 moderately decreased HUVEC migration, as quan-
tified by a reduced percentage of cells that migrated into the
gap created by the scratch. Bevacizumab exhibited similar
inhibitory effects, consistent with VEGF’s motility-
promoting role [27]. The combination of both drugs exhibited
an additive inhibition when compared to either drug alone in
the scratch filling assay.
EC apoptosis provided another opportunity to evaluate
TRC105 and bevacizumab in both regular and limited medi-
um. In the presence of multiple growth factors, TRC105 and
bevacizumab exhibited similar potency in inducing HUVEC
apoptosis (Fig. 4a). In limited medium, where VEGF is es-
sentially the only growth factor, TRC105 was also active and
exhibited dose-dependent induction of HUVEC apoptosis
(Fig. 4b). These findings are in agreement with previous
observations that SN6j, the parent antibody of TRC105, also
led to increased HUVEC apoptosis in vitro [18]. However,
there were no additive effects by combining both drugs.
Lastly, we explored the molecular mechanisms underlying
the ability of TRC105 to block HUVEC function. Since
endoglin is a type III receptor for TGF-β and BMP, we
investigated the effects of TRC105 on Smad signaling, path-
ways known to play pivotal roles in EC proliferation and
viability. In assessing Smad phosphorylation (Fig. 5), three
doses of TRC105 were chosen: 0.2, 100, and 1,000 μg/ml. A
dose of 0.2 μg/ml is the target concentration predicted to
saturate endoglin on cell surface [16]. Doses of 100 and
1,000μg/ml fall within or close to the range of TRC105 plasma
concentrations (200–600 μg/ml) achieved in cancer patients
following dosing at the recommended phase 2 dose [16].
While endoglin’s role in canonical TGF-β signaling is well
documented [28], recent data indicate that BMP-9 and −10 are
the important endoglin ligands that mediate Smad 1/5/8 phos-
phorylation needed for activation of primary EC [10, 29]. Our
data corroborate that BMP-9 effectively stimulates Smad 1/5/
8 phosphorylation (more than 30 fold induction), while
TGF-β1 only modestly stimulates Smad 2/3 phosphorylation
(approximately 5 fold induction). Our observation is consis-
tent with the model suggesting that the BMP9-ALK1-Smad1/
5/8 and the TGFβ-ALK5-Smad2/3 axes co-exist in parallel in
primary human EC [10].
When HUVEC were pre-treated with TRC105, BMP-9-
induced Smad 1/5/8 phosphorylation was inhibited by 50 %,
even at the lowest dose of 0.2 μg/ml (Fig. 5b). In contrast,
TGF-β1-induced Smad 2/3 phosphorylation was less affected
(<20 % inhibition). It is well established that Smad 1/5/8
signaling promotes EC activation. Therefore, the inhibition
of this pathway exerted by TRC105 would lead to EC deac-
tivation, contributing to the anti-angiogenic, anti-tumor func-
tion of TRC105.
In addition to blocking BMP9/Smad1/5/8 signaling, other
mechanisms may be responsible for TRC105 anti-angiogenic
function. For example, biomarker analyses from cancer pa-
tients treated with escalating doses of TRC105 revealed sig-
nificant increases of soluble endoglin (sEnd) after TRC105
administration [30]. Kumar et al. proposed two mechanisms
as to how TRC105 could induce sEnd shedding [31]. First,
TRC105 could stabilize endoglin/MMP-14 complexes on the
cell surface; second, TRC105 could induce MMP-14 gene
expression to facilitate enzymatic cleavage of endoglin. In
either event, sEnd would be released and serve as a trap for
its ligand BMP-9, further diminishing the BMP9/Smad 1/5/8
pathway [32]. Another mechanism may involve the intracel-
lular domain of endoglin. This domain contains important
structural elements that serve as docking sites for multiple
adaptor proteins, such as zyxin, zyxin-related protein 1 [33],
β-arrestin2 [34], and GIPC [35]. It remains unclear how
TRC105 binding to endoglin would affect these proteins and
what role (s) the intracellular domain of endoglin plays in
TRC105 function.
Clinically relevant doses of TRC105 were tested in these
in vitro cell-based assays and could facilitate our understand-
ing of the efficacy in vivo. Based on the superior effects of
TRC105 and bevacizumab in HUVEC tube formation assays,
the combination of both drugs has the potential to increase
drug efficacy and reduce resistance. Currently, developing
rationale-based combinations of multiple anti-angiogenic
agents is a favored strategy to overcome resistance in the
clinic [36]. Bevacizumab has been successfully added to
chemo- and radiotherapy regimens and has significantly im-
proved patient outcomes [37]. In the case of TRC105 and
bevacizumab, with each drug targeting an independent path-
way, more effective blockage of angiogenesis is expected.
However, caution needs to be taken when determining drug
dosing, relative ratio, frequency of administration, etc., to
prevent the possible convergence of downstream effectors
becoming exhausted or saturated.
In summary, we have demonstrated that the combination of
TRC105 and bevacizumab led to greater inhibition in
HUVEC functional assays, such as tube formation and migra-
tion, than either drug alone. We also explored Smad signaling
and confirmed that diminished BMP9/Smad 1/5/8 signaling is
a mechanism contributing to TRC105’s anti-angiogenic, anti-
tumor effect. The superior potency demonstrated by the drug
Invest New Drugs (2014) 32:851–859 857
combination advocates their co-administration in vivo as a
therapeutic strategy.
Acknowledgments We would like to thank the staff from Light Mi-
croscopy Core Facility in Duke University Medical Center. This work
was supported by a grant from Tracon Pharmaceuticals, Inc.
Conflict of interest Y Liu and H Tian have no conflicts to disclose. GC
Blobe is a consultant/advisory board member and has received honorar-
ium from Genentech and Roche. CP Theuer is the president and CEO of
Tracon Pharmaceuticals, Inc. HI Hurwitz has received research funding
from F Hoffman-La Roche, Amgen, Pfizer, Tracon Pharmaceuticals,
Genentech, Sanofi, Morphotek and GSK. HI Hurwitz is a consultant/
advisory board member for GlaxoSmithKline, Novartis, Genentech,
Roche, Sanofi, Regeneron, BMS, Bayer, and Tracon. AB Nixon has
received research funding from Tracon Pharmaceuticals, F Hoffman-La
Roche, Amgen, Pfizer and is a consultant/advisory board member for
GlaxoSmithKline and Novartis.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other
diseases. Nature 407(6801):249–257
2. Folkman J (2007) Angiogenesis: an organizing principle for drug
discovery? Nat Rev 6(4):273–286
3. Hurwitz H, Fehrenbacher L, NovotnyW, Cartwright T, Hainsworth J,
HeimW, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe
G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorec-
tal cancer. N Engl J Med 350(23):2335–2342
4. Van Meter ME, Kim ES (2010) Bevacizumab: current updates in
treatment. Curr Opin Oncol 22(6):586–591. doi:10.1097/CCO.
0b013e32833edc0c
5. Jayson GC, Hicklin DJ, Ellis LM (2012) Antiangiogenic therapy-
evolving view based on clinical trial results. Nat Rev Clin Oncol 9(5):
297–303. doi:10.1038/nrclinonc.2012.8
6. Samant RS, Shevde LA (2011) Recent advances in anti-angiogenic
therapy of cancer. Oncotarget 2(3):122–134
7. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J,
Letarte M (1992) Endoglin is a component of the transforming
growth factor-beta receptor system in human endothelial cells. J
Biol Chem 267(27):19027–19030
8. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King
SW, Letarte M, Vitetta ES, Thorpe PE (1995) Up-regulation of
endoglin on vascular endothelial cells in human solid tumors:
implications for diagnosis and therapy. Clin Cancer Res 1(12):
1623–1634
9. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G,
Thorikay M, Mummery C, Arthur HM, ten Dijke P (2004) Endoglin
promotes endothelial cell proliferation and TGF-beta/ALK1 signal
transduction. EMBO J 23(20):4018–4028
10. Nolan-Stevaux O, Zhong W, Culp S, Shaffer K, Hoover J,
Wickramasinghe D, Ruefli-Brasse A (2012) Endoglin requirement
for BMP9 signaling in endothelial cells reveals new mechanism of
action for selective anti-endoglin antibodies. PLoS ONE 7(12):
e50920. doi:10.1371/journal.pone.0050920
11. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras
P, ten Dijke P (2002) Balancing the activation state of the
endothelium via two distinct TGF-beta type I receptors.
EMBO J 21(7):1743–1753
12. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM
(2008) Endoglin (CD105): a marker of tumor vasculature and poten-
tial target for therapy. Clin Cancer Res 14(7):1931–1937
13. SeonBK, Haruta Y,Matsuno F, Haba A, Takahashi N, She X, Harada
N, Uneda S, Tsujie M, Tsujie T, Toi H, Tsai H (2010) Receptor-
targeted anticancer therapy. Immunol Res 46(1–3):189–191. doi:10.
1007/s12026-009-8131-8
14. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M (2010)
Targeting cancer vasculature via endoglin/CD105: a novel antibody-
based diagnostic and therapeutic strategy in solid tumours.
Cardiovasc Res 86(1):12–19. doi:10.1093/cvr/cvp332
15. SeonBK, Haba A,Matsuno F, Takahashi N, TsujieM, She X, Harada
N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y (2011) Endoglin-
targeted cancer therapy. Curr Drug Deliv 8(1):135–143
16. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg
WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh
BR, Gordon MS (2012) A phase I first-in-human study of TRC105
(Anti-Endoglin Antibody) in patients with advanced cancer. Clin
Cancer Res Off J Am Assoc Cancer Res 18(17):4820–4829. doi:
10.1158/1078-0432.CCR-12-0098
17. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a conve-
nient and inexpensive method for analysis of cell migration in vitro.
Nat Protoc 2(2):329–333
18. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H, Seon BK
(2008) Anti-tumor activity of an anti-endoglin monoclonal antibody
is enhanced in immunocompetent mice. Int J Cancer 122(10):2266–
2273. doi:10.1002/ijc.23314
19. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao
Q, Pukac L, Lowik CW, ten Dijke P (2007) BMP-9 signals via ALK1
and inhibits bFGF-induced endothelial cell proliferation and VEGF-
stimulated angiogenesis. J Cell Sci 120(Pt 6):964–972. doi:10.1242/
jcs.002949
20. Haruta Y, Seon BK (1986) Distinct human leukemia-associated cell
surface glycoprotein GP160 defined by monoclonal antibody SN6.
Proc Natl Acad Sci U S A 83(20):7898–7902
21. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK,
Berse B, Jackman RW, Dvorak AM, Dvorak HF (1993) Vascular
permeability factor (VPF, VEGF) in tumor biology. Cancer
Metastasis Rev 12(3–4):303–324
22. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and
its receptors. Nat Med 9(6):669–676. doi:10.1038/nm0603-669
23. Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR,
Franco M, Paez-Ribes M, Cordiner R, Fuxe J, Johansson BR,
Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K
(2013) Deficiency for endoglin in tumor vasculature weakens the
endothelial barrier to metastatic dissemination. J Exp Med 210(3):
563–579. doi:10.1084/jem.20120662
24. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabeu C,
Vary CP (2004) Endoglin controls cell migration and composition of
focal adhesions: function of the cytosolic domain. J Biol Chem
279(26):27440–27449
25. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S
(2000) CD105 antagonizes the inhibitory signaling of transforming
growth factor beta1 on human vascular endothelial cells. FASEB J
14(1):55–64
26. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J,
Mummery C, Karlsson S, ten Dijke P (2003) Activin receptor-like
kinase (ALK) 1 is an antagonistic mediator of lateral TGFbeta/ALK5
signaling. Mol Cell 12(4):817–828
27. Urbich C, Aicher A, Heeschen C, Dernbach E, HofmannWK, Zeiher
AM, Dimmeler S (2005) Soluble factors released by endothelial
progenitor cells promote migration of endothelial cells and cardiac
858 Invest New Drugs (2014) 32:851–859
resident progenitor cells. J Mol Cell Cardiol 39(5):733–742. doi:10.
1016/j.yjmcc.2005.07.003
28. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP,
Bernabeu C (2005) Interaction and functional interplay between
endoglin and ALK-1, two components of the endothelial
transforming growth factor-beta receptor complex. J Cell Physiol
204(2):574–584. doi:10.1002/jcp.20311
29. Alt A, Miguel-Romero L, Donderis J, Aristorena M, Blanco FJ,
Round A, Rubio V, Bernabeu C, Marina A (2012) Structural and
functional insights into endoglin ligand recognition and binding.
PLoS ONE 7(2):e29948. doi:10.1371/journal.pone.0029948
30. Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP,
LeeNY,HurwitzHI,NixonAB (2014)Modulation of circulating protein
biomarkers following TRC105 (anti-endoglin antibody) treatment in
patients with advanced cancer. Cancer Med. doi:10.1002/cam4.207
31. Kumar S, Pan CC, Bloodworth JC, Nixon A, Theuer C, Hoyt DG,
Lee NY (2013) Antibody-directed coupling of endoglin and MMP-
14 is a key mechanism for endoglin shedding and deregulation of
TGF-beta signaling. Oncogene. doi:10.1038/onc.2013.386
32. Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW,
Solban N, Sako D, Pearsall RS, Underwood KW, Seehra J, Kumar R,
Grinberg AV (2011) Soluble endoglin specifically binds bone
morphogenetic proteins 9 and 10 via its orphan domain, inhibits
blood vessel formation, and suppresses tumor growth. J Biol Chem
286(34):30034–30046. doi:10.1074/jbc.M111.260133
33. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM, Banville D,
Vary CP, Bernabeu C (2004) Endoglin regulates cytoskeletal
organization through binding to ZRP-1, a member of the Lim
family of proteins. J Biol Chem 279(31):32858–32868. doi:10.
1074/jbc.M400843200
34. Lee NY, Blobe GC (2007) The interaction of endoglin with beta-
arrestin2 regulates transforming growth factor-beta-mediated ERK
activation and migration in endothelial cells. J Biol Chem 282(29):
21507–21517. doi:10.1074/jbc.M700176200
35. Lee NY, Ray B, How T, Blobe GC (2008) Endoglin promotes
transforming growth factor beta-mediated Smad 1/5/8 signaling and
inhibits endothelial cell migration through its association with GIPC.
J Biol Chem 283(47):32527–32533. doi:10.1074/jbc.M803059200
36. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current chal-
lenges and future perspectives. Cancer Lett 320(2):130–137. doi:10.
1016/j.canlet.2012.03.008
37. Abdollahi A, Folkman J (2010) Evading tumor evasion: current
concepts and perspectives of anti-angiogenic cancer therapy. Drug
Resist Updat 13(1–2):16–28. doi:10.1016/j.drup.2009.12.001
Invest New Drugs (2014) 32:851–859 859
